MX2013001385A - Construcciones de fusion de proteina que tienen propiedades tromboliticas y anticoagulantes. - Google Patents
Construcciones de fusion de proteina que tienen propiedades tromboliticas y anticoagulantes.Info
- Publication number
- MX2013001385A MX2013001385A MX2013001385A MX2013001385A MX2013001385A MX 2013001385 A MX2013001385 A MX 2013001385A MX 2013001385 A MX2013001385 A MX 2013001385A MX 2013001385 A MX2013001385 A MX 2013001385A MX 2013001385 A MX2013001385 A MX 2013001385A
- Authority
- MX
- Mexico
- Prior art keywords
- thrombin
- fusion constructs
- protein fusion
- blood
- anticoagulant properties
- Prior art date
Links
- 230000002429 anti-coagulating effect Effects 0.000 title 1
- 239000003146 anticoagulant agent Substances 0.000 title 1
- 230000012743 protein tagging Effects 0.000 title 1
- 230000002537 thrombolytic effect Effects 0.000 title 1
- 108090000190 Thrombin Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229960004072 thrombin Drugs 0.000 abstract 2
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- 102000013566 Plasminogen Human genes 0.000 abstract 1
- 108010051456 Plasminogen Proteins 0.000 abstract 1
- 108010001014 Plasminogen Activators Proteins 0.000 abstract 1
- 102000001938 Plasminogen Activators Human genes 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 230000035602 clotting Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 230000006623 intrinsic pathway Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 229940012957 plasmin Drugs 0.000 abstract 1
- 229940127126 plasminogen activator Drugs 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Marine Sciences & Fisheries (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención describe proteínas híbridas novedosas que tienen tanto propiedades activadoras de plasminógeno y antitrombóticas, incluyendo acción específica en coágulos que los provee como altamente ventajosos para el tratamiento de trastornos circulatorios que involucran la formación de coágulos de fibrina debido al daño del tejido subyacente en los vasos sanguíneos que llevan al infarto al miocardio, accidentes cerebrovasculares, etc.; también se describen nuevas proteínas y métodos para obtener las mismas, que ayudan a disolver los coágulos de sangre al activar el plasminógeno en una manera dependiente de plasmina o trombina y también inhibir tanto la actividad y la generación de trombina a través de la trayectoria intrínseca de la coagulación sanguínea.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1845DE2010 | 2010-08-05 | ||
| PCT/IB2011/001825 WO2012017310A2 (en) | 2010-08-05 | 2011-08-05 | Protein fusion constructs possessing thrombolytic and anticoagulant properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013001385A true MX2013001385A (es) | 2013-07-15 |
Family
ID=45559872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001385A MX2013001385A (es) | 2010-08-05 | 2011-08-05 | Construcciones de fusion de proteina que tienen propiedades tromboliticas y anticoagulantes. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9150844B2 (es) |
| EP (1) | EP2600891B1 (es) |
| JP (1) | JP6234224B2 (es) |
| KR (1) | KR20130099027A (es) |
| CN (1) | CN103179982A (es) |
| AR (1) | AR082588A1 (es) |
| AU (1) | AU2011287360A1 (es) |
| BR (1) | BR112013002739A2 (es) |
| CA (1) | CA2807749C (es) |
| CL (1) | CL2011001887A1 (es) |
| MX (1) | MX2013001385A (es) |
| WO (1) | WO2012017310A2 (es) |
| ZA (1) | ZA201301032B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104602701B (zh) | 2012-07-05 | 2019-04-16 | 哈达斯特医疗研究服务和开发有限公司 | 作为抗纤维蛋白溶解剂的纤维蛋白溶酶原活化剂的突变体 |
| BR102017005783A2 (pt) * | 2017-03-21 | 2018-10-02 | Fund Butantan | processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos |
| WO2024060167A1 (zh) * | 2022-09-23 | 2024-03-28 | 庄伟哲 | 靶向整合素αIIbβ3的含组织纤维溶酶原活化剂或其变异体的融合蛋白质及其应用 |
| US20240269240A1 (en) * | 2023-02-15 | 2024-08-15 | Blue Blood Biotech Corporation | Compositions and methods for treating hair loss or facilitating hair growth |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE67036B1 (en) * | 1987-06-04 | 1996-05-15 | Zymogenetics Inc | Tissue plasminogen activator analogs having modified growth factor domains |
| DK299087D0 (da) * | 1987-06-12 | 1987-06-12 | Novo Industri As | Proteins and derivatives thereof |
| KR940009084B1 (ko) * | 1988-05-18 | 1994-09-29 | 체크 포인트 시스템스, 인코오퍼레이티드 | 자기 및 공명회로 검출용 안테나 시스템 |
| AU646633B2 (en) * | 1989-02-17 | 1994-03-03 | Codon | Soluble analogs of thrombomodulin |
| US5256770A (en) | 1990-04-09 | 1993-10-26 | Schering Ag | Oxidation resistant thrombomodulin analogs |
| US5466668A (en) | 1989-04-28 | 1995-11-14 | Schering Aktiengesellschaft | Superior thrombomodulin analogs for pharmaceutical use |
| GB8927722D0 (en) * | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| WO1992000325A1 (en) | 1990-06-27 | 1992-01-09 | Mochida Pharmaceutical Co., Ltd. | Anticoagulant polypeptides |
| WO1994016085A2 (en) * | 1992-12-30 | 1994-07-21 | Zymogenetics, Inc. | Hybrid proteins having cross-linking and tissue-binding activities |
| DE4442665A1 (de) | 1994-11-30 | 1996-06-05 | Gruenenthal Gmbh | Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften |
| IN190822B (es) | 1998-12-24 | 2003-08-23 | Council Scient Ind Res | |
| CA2406583A1 (en) * | 2000-05-10 | 2001-11-15 | Novo Nordisk A/S | Pharmaceutical composition comprising a factor viia and a factor xiii |
| US6632791B1 (en) | 2000-06-21 | 2003-10-14 | Schering Aktiengesellschaft | Thrombomodulin analogs for pharmaceutical use |
| CA2483909A1 (en) | 2002-05-01 | 2003-11-13 | Schering Aktiengesellschaft | Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| CN1480466A (zh) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | 一类溶栓抗凝双功能融合蛋白及应用 |
| US8124588B2 (en) * | 2003-12-18 | 2012-02-28 | Justus Liebig Universität Giessen | Chimeric plasminogen activators and their pharmaceutical use |
| ATE466868T1 (de) | 2005-04-20 | 2010-05-15 | Viromed Co Ltd | Zusammensetzungen und verfahren zur trennung von fusionsproteinen |
| AR071169A1 (es) | 2008-03-31 | 2010-06-02 | Council Scient Ind Res | Variantes de la estreptoquinasa que contienen cisteina y sus formas covalentemente modificadas |
-
2011
- 2011-08-05 EP EP11814173.8A patent/EP2600891B1/en active Active
- 2011-08-05 MX MX2013001385A patent/MX2013001385A/es not_active Application Discontinuation
- 2011-08-05 WO PCT/IB2011/001825 patent/WO2012017310A2/en active Application Filing
- 2011-08-05 CA CA2807749A patent/CA2807749C/en active Active
- 2011-08-05 BR BR112013002739A patent/BR112013002739A2/pt not_active IP Right Cessation
- 2011-08-05 CL CL2011001887A patent/CL2011001887A1/es unknown
- 2011-08-05 KR KR1020137005514A patent/KR20130099027A/ko not_active Application Discontinuation
- 2011-08-05 AU AU2011287360A patent/AU2011287360A1/en not_active Abandoned
- 2011-08-05 JP JP2013522316A patent/JP6234224B2/ja active Active
- 2011-08-05 US US13/814,412 patent/US9150844B2/en active Active
- 2011-08-05 AR ARP110102867A patent/AR082588A1/es not_active Application Discontinuation
- 2011-08-05 CN CN2011800482916A patent/CN103179982A/zh active Pending
-
2013
- 2013-02-07 ZA ZA2013/01032A patent/ZA201301032B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011287360A1 (en) | 2013-02-21 |
| JP6234224B2 (ja) | 2017-11-22 |
| BR112013002739A2 (pt) | 2019-09-24 |
| WO2012017310A3 (en) | 2012-07-19 |
| KR20130099027A (ko) | 2013-09-05 |
| JP2013535211A (ja) | 2013-09-12 |
| US20130136731A1 (en) | 2013-05-30 |
| CN103179982A (zh) | 2013-06-26 |
| EP2600891B1 (en) | 2018-01-17 |
| ZA201301032B (en) | 2014-04-30 |
| WO2012017310A2 (en) | 2012-02-09 |
| EP2600891A4 (en) | 2014-01-01 |
| AR082588A1 (es) | 2012-12-19 |
| CL2011001887A1 (es) | 2012-02-03 |
| EP2600891A2 (en) | 2013-06-12 |
| CA2807749A1 (en) | 2012-02-09 |
| CA2807749C (en) | 2023-02-28 |
| US9150844B2 (en) | 2015-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2547355A4 (en) | TFPI HEMMER AND USE METHOD THEREFOR | |
| EA201270703A1 (ru) | Ингибиторы трипсиноподобных сериновых протеаз, их получение и применение | |
| WO2010071894A3 (en) | Tfpi inhibitors and methods of use | |
| MX2010003095A (es) | Antidotos para inhibidores del factor xa y metodos para usar los mismos. | |
| WO2010056765A3 (en) | Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents | |
| EA201590910A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
| MX2013001385A (es) | Construcciones de fusion de proteina que tienen propiedades tromboliticas y anticoagulantes. | |
| GB2462228A (en) | Providing hemostasis in anticoagulated blood by using zeolites | |
| EP2407561A3 (en) | A method for the preparation of recombinant human fibrinogen | |
| EA200800667A1 (ru) | Аптамеры, связывающие тромбин с высокой аффинностью | |
| WO2012006516A3 (en) | Protein kinase c activators and anticoagulant for the treatment of stroke | |
| MX2016007711A (es) | Serpinas modificadas para el tratamiento de trastornos de la coagulacion. | |
| WO2012020412A3 (en) | Fibrin based scaffold, preparation and use thereof | |
| MX362098B (es) | El uso de células derivadas de tejido del cordón umbilical y kits que contienen las mismas para el tratamiento de enfermedad vascular periférica. | |
| PH12014501169A1 (en) | Thrombin-binding antibody molecules and uses thereof | |
| PH12014501176A1 (en) | Anticoagulant reversal agents | |
| MY167803A (en) | Coagulation controlling agents and devices comprising the same | |
| PA8816101A1 (es) | Clorotiofeno - amidas como inhibidores de los factores de coagulacion xa y trombina | |
| GB201201753D0 (en) | Therapeutic agents with improved fibrinogen binding | |
| WO2010100570A3 (en) | Activated leukocyte composition | |
| RU2013152864A (ru) | Высокоселективный ингибитор контактной активации на основе инфестина 4 | |
| MX2015007625A (es) | Composiciones sellantes. | |
| FR2902011B1 (fr) | Utilisation de fractions cellulaires du tissu adipeux pour la regeneration tissulaire post irradiation | |
| WO2012097084A3 (en) | Tenomodulin (tnmd) isoforms and uses thereof | |
| SG10201807066UA (en) | Peptides and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |